Biologic discovery of novel therapeutics is one of the most important and popular areas of research, improving medical advances through engineering of antibodies or other proteins for cancer treatment, infectious diseases, and inflammatory or autoimmune disorders. Monoclonal antibodies, antibody-drug conjugates, and single-domain antibody variants have become invaluable for their robust recognition and downstream regulation of human immunologic processes.
Using antibodies to recognize cancer-related antigens and stimulate an immune attack has become increasingly important in current and future cancer treatments. Likewise, neutralizing antibodies for autoimmune and inflammatory diseases bind to and prevent pro-inflammatory factors from exacerbating the immune response. The rise of synthetic biology has removed much of the guesswork, transforming the drug discovery process from serendipity into rational design for identifying and producing safer, more effective therapies with less chance of late-stage failures in clinical trials.
With all drug discovery systems, the challenges are always the time and resources required to build new biological drug candidates, such as human monoclonal antibodies, and to get the highest specificity and safest drug delivery possible. With the introduction of high-throughput gene synthesis on the BioXp™ 3200 system, antigen-binding sequences can be custom-designed for increased specificity and mutant libraries can be constructed with unprecedented speeds at competitive prices.
Multi-fragment assembly cloning is ideal for creating up to 16 scFv variants overnight. And with Vmax™ X2 cells, powered by Gibson Assembly® technology, expression of single-domain antibodies are expressed faster, with higher yields in a simpler workflow, negating the need for E. coli protein expression strains.